Form 4: Cytek Director Converts RSUs to Common Stock

Cytek Biosciences Director Michael Holder converted 2,181 Restricted Stock Units into common stock, increasing his direct beneficial ownership.

Summary

• Michael Holder, a Director at Cytek Biosciences, Inc. (CTKB), converted 2,181 Restricted Stock Units (RSUs) into common stock.
• The transaction occurred on August 18, 2025, as part of a pre-defined vesting schedule.
• Following this conversion, Michael Holder directly beneficially owns 10,178 shares of common stock.
• He also continues to hold 16,000 Restricted Stock Units.
• The RSUs converted at a price of $0, indicating they are part of an equity compensation plan.
• The RSU award has a complex vesting schedule, with portions vesting on specific dates: 2/36 on August 18, 2024; 3/36 on November 18, 2024 and each November 18 thereafter; 4/36 on March 10, 2025 and each March 10 thereafter; 2/36 on May 18, 2025 and each May 18 thereafter; and 3/36 on August 18, 2025 and each August 18 thereafter, until fully vested.

Sentiment

Score: 7

Explanation: The filing indicates a routine insider transaction related to equity compensation. The conversion of RSUs into common stock by a director is generally viewed positively as it aligns insider interests with shareholders, without indicating any immediate concerns or significant strategic shifts.

Positives

• Director Michael Holder's conversion of RSUs into common stock indicates continued alignment of his interests with shareholders.
• The transaction is part of a pre-defined equity compensation plan, reflecting standard corporate governance practices.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholders due to direct ownership of common stock.

Next Steps

• Continued vesting of remaining Restricted Stock Units according to the established schedule.

Key Dates

Recommendation

This Form 4 filing details a routine conversion of Restricted Stock Units (RSUs) by a director as part of an equity compensation plan. Such transactions are generally expected and do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation. The director's increased direct ownership of common stock aligns their interests with shareholders, which is a positive, but not a catalyst for a 'buy' recommendation on its own. There are no new material financial or operational details to alter a current investment thesis.

Keywords

Cytek Biosciences, CTKB, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Director Ownership, Equity Compensation, Michael Holder